This report examines how biomarker testing improves cancer outcomes by enabling more precise diagnosis, treatment selection, and monitoring. It identifies gaps in testing adoption across regions and cancer types, driven by infrastructure limitations, reimbursement barriers, and clinical awareness. The analysis shows that biomarker-guided therapies can improve survival, reduce unnecessary treatments, and lower total system costs. Case studies illustrate how earlier and more consistent testing leads to better patient stratification. The report emphasizes the need for coordinated policy, laboratory capacity investment, and clinician education to fully realize the value of precision oncology.

Join for free to read